CA2749817A1 - Methods of determining patient response by measurement of her-2 expression - Google Patents

Methods of determining patient response by measurement of her-2 expression Download PDF

Info

Publication number
CA2749817A1
CA2749817A1 CA2749817A CA2749817A CA2749817A1 CA 2749817 A1 CA2749817 A1 CA 2749817A1 CA 2749817 A CA2749817 A CA 2749817A CA 2749817 A CA2749817 A CA 2749817A CA 2749817 A1 CA2749817 A1 CA 2749817A1
Authority
CA
Canada
Prior art keywords
homodimers
amount
subject
samples
threshold level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2749817A
Other languages
French (fr)
Inventor
Michael Bates
Jennifer W. Cook
Gundo Diedrich
Laurie Goodman
Ali Mukherjee
Gordon Parry
Jeff Sperinde
Stephen John Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratory Corp of America Holdings
Original Assignee
Laboratory Corp of America Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42340111&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2749817(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratory Corp of America Holdings filed Critical Laboratory Corp of America Holdings
Publication of CA2749817A1 publication Critical patent/CA2749817A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

Methods are provided for determining or otherwise assessing the response of a patient to treatment, in particular, to cancer treatment. The methods include the analysis of samples for the presence or the absence of HER2 markers alone or in conjunction with other biomarkers, such as HER3 markers. In certain examples, the probable time to progression can be determined by first determining HER2 positive patients and then further stratifying by using the presence or the absence of a second biomarker (e.g, HER3 markers).
In addition, the data can be used to track a patient's response to a treatment regimen, assessing the expected success of treating a patient using a particular regiment, determining the effects of a treatment regiment or for categorizing a patient in order to create a homogenous group for a clinical trial.

Claims (24)

1. A method to correlate the relative levels of the amount of at least one of Her-2 or Her-2 homodimers in a biological sample from a subject with a prognosis for the likelihood that the subject will respond to treatment with a Her-2 acting agent comprising:
(a) detecting in a biological sample from the subject's cancer the amount of at least one of Her-2 or Her-2 homodimers; and (b) correlating the amount of Her-2 or Her-2 homodimers to a prognosis for the likelihood that the subject will respond to treatment with a Her-2 acting agent.
2. The method of claim 1, wherein the cancer is at least one of metastatic or primary early stage (i.e., adjuvant) breast cancer.
3. The method of claim 1, wherein if the amount of the at least one of the Her-2 or Her-2 homodimers is equal to or above a first threshold level, the subject's prognosis is to be likely to respond to the Her-2 acting agent.
4. The method of claim 1, wherein if the amount of the at least one of the Her-2 or Her-2 homodimers is equal to or above a second threshold level higher than the first threshold level, the subject's prognosis is to be unlikely to respond to the Her-2 acting agent.
5. The method of claim 1, wherein a predetermined measure is created by dividing a plurality of subject samples into at least three subgroups, wherein the first subgroup comprises samples having the Her-2 or Her-2 homodimers at a low level, wherein the low level comprises having an amount of the at least one of the Her-2 or Her-2 homodimers equal to or below a first threshold level, and the samples having an amount of the at least one of the Her-2 or Her-2 homodimers above the first threshold comprise samples having a high level of the Her-2 or Her-2 homodimers, and wherein the samples having a high level of the Her-2 or Her-2 homodimers is then divided into two subgroups, a very high subgroup comprising samples having an amount of the at least one of the Her-2 or Her-2 homodimers equal to above a second threshold level higher than the first threshold level, and a moderately high subgroup comprising samples having an amount of the at least one of the Her-2 or Her-2 homodimers greater than or equal to the first threshold level and less than or equal to the second threshold level.
6. The method of claim 1, wherein the amount of Her-2 homodimers is measured using an assay capable of measuring and/or quantifying an amount of protein-protein interactions in a sample.
7. The method of claim 5, wherein the moderately high Her-2 subgroup is further subdivided into subgroups that express at least one other biomarker.
8. The method of claim 7, wherein the at least one other biomarker comprises at least one of FOXM1, PRAME, Bc12, STK15, CEGP1, Ki-67, GSTM1, CA9, PR, BBC3, NME1, SURV, GATA3, TFRC, YB-1, DPYD, GSTM3, RPS6KB1, Src, Chk1, ID1, EstR1, p27, CCNB1, XIAP, Chk2, CDC25B, IGF1R, AK055699, P13KC2A, TGFB3, BAGI1, CYP3A4, EpCAM, VEGFC, pS2, hENT1, WISP1, HNF3A, NFKBp65, BRCA2, EGFR, TK1, VDR, Contig51037, pENT1, EPHX1, IF1A, CDH1, HIF1.alpha., IGFBP3; CTSB, Her3, DIABLO, VEGF, CD31, KDR, or p95.
9. The method of claim 7, wherein a predetermined measure is generated by dividing the Her-2 medium and/or Her-2 high samples into at least two subgroups, based on the level of the at least one other biomarker.
10. The method of claim 9, wherein the moderately high subgroup is further divided based upon Her-3 expression wherein a high level comprises having Her-3 above a first threshold level and a low level comprises having Her-3 below a second threshold level, and wherein a subject with moderately high levels of the at least one Her-2 and/or Her-2 dimers and low levels of Her-3 is likely to respond to the Her-2 acting agent and/or wherein a subject with moderately high levels of the at least one Her-2 and/or Her-2 dimers and high levels of Her-3 is unlikely or less likely to respond to the Her-2 acting agent..
11. The method of claim 10, wherein the Her-3 expression comprises Her-3, Her-homodimers, or Her-3/Her-2 heterodimers.
12. The method of claim 11, wherein the amount of Her-3 homodimers and/or Her-2/Her-3 heterodimers is measured using an assay capable of measuring and/or quantifying an amount of protein-protein interactions in a sample.
13. A method for predicting whether a subject with a cancer and being treated with a Her-2 acting agent is likely to have a significant event comprising the steps of:
(a) detecting in a biological sample from the subject's cancer the amount of at least one of Her-2 or Her-2 homodimers; and (b) correlating the amount of Her-2 or Her-2 homodimers to the likelihood that the subject will have a significant event.
14. The method of claim 13, wherein the cancer is at least one of metastatic or primary early stage (i.e., adjuvant) breast cancer.
15. The method of claim 13, wherein the significant event is a reduced time between diagnosis with the cancer and at least one of primary diagnosis, progression of the cancer from one stage to a more advanced stage, progression to metastatic disease, relapse, surgery or death.
16. The method of claim 13, further comprising predicting a time course during which the significant event can occur.
17. The method of claim 13, wherein if the amount of the at least one of the Her-2 or Her-2 homodimers is equal to or below a first threshold level, the significant event is that the subject is less likely to respond to the Her-2 acting agent.
18. The method of claim 13, wherein if the amount of the at least one of the Her-2 or Her-2 homodimers is equal to or above a second threshold level higher than the first threshold level, the subject's prognosis is to be unlikely to respond to the Her-2 acting agent.
19 The method of claim 13, wherein a predetermined measure is created by dividing a plurality of subject samples into at least three subgroups, wherein the first subgroup comprises samples having the Her-2 or Her-2 homodimers at a low level, wherein the low level comprises having an amount of the at least one of the Her-2 or Her-2 homodimers equal to or below a first threshold level, and the samples having an amount of the at least one of the Her-2 or Her-2 homodimers equal to or above the first threshold comprise samples having a high level of the Her-2 or Her-2 homodimers, and wherein the samples having a high level of the Her-2 or Her-2 homodimers is then divided into two subgroups, a very high subgroup comprising samples having an amount of the at least one of the Her-2 or Her-2 homodimers equal to or above a second threshold level higher than the first threshold level, and a moderately high subgroup comprising samples having an amount of the at least one of the Her-2 or Her-2 homodimers greater than or equal to the first threshold level and less than or equal to the second threshold level.
20. The method of claim 13, wherein the amount of Her-2 homodimers is measured using an assay capable of measuring and/or quantifying an amount of protein-protein interactions in a sample.
21. The method of claim 13, wherein the medium subgroup is further subdivided into subgroups that express at least one other biomarker.
22. The method of claim 21, wherein the at least one other biomarker comprises FOXM1, PRAME, Bc12, STK15, CEGP1, Ki-67, GSTM1, CA9, PR, BBC3, NME1, SURV, GATA3, TFRC, YB-1, DPYD, GSTM3, RPS6KB1, Src, Chk1, ID1, EstR1, p27, CCNB1, XIAP, Chk2, CDC25B, IGF1R, AK055699, P13KC2A, TGFB3, BAGI1, CYP3A4, EpCAM, VEGFC, pS2, hENT1, WISP1, HNF3A, NFKBp65, BRCA2, EGFR, TK1, VDR, Contig51037, pENT1, EPHX1, IF1A, CDH1, HIF1.alpha., IGFBP3; CTSB, Her3, DIABLO, VEGF, CD31, KDR, or p95.
23. The method of claim 21, wherein a predetermined measure is generated by dividing the Her-2 moderately high samples into at least two subgroups likely to have different time courses for having a significant event, based on the level of the at least one other biomarker.
24. A kit to correlate the relative levels of the amount of at least one of Her-2 or Her-2 homodimers in a biological sample from a subject with a prognosis for the likelihood that the subject will respond to treatment with a Her-2 acting agent comprising:
(a) reagents for detecting in a biological sample from the subject's cancer the amount of at least one of Her-2 or Her-2 homodimers; and (b) instructions for correlating the amount of Her-2 or Her-2 homodimers to a prognosis for the likelihood that the subject will respond to treatment with a Her-2 acting agent.
CA2749817A 2009-01-15 2010-01-15 Methods of determining patient response by measurement of her-2 expression Abandoned CA2749817A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14502909P 2009-01-15 2009-01-15
US61/145,029 2009-01-15
PCT/US2010/021272 WO2010083463A1 (en) 2009-01-15 2010-01-15 Methods of determining patient response by measurement of her-2 expression

Publications (1)

Publication Number Publication Date
CA2749817A1 true CA2749817A1 (en) 2010-07-22

Family

ID=42340111

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2749817A Abandoned CA2749817A1 (en) 2009-01-15 2010-01-15 Methods of determining patient response by measurement of her-2 expression

Country Status (12)

Country Link
US (3) US20100233732A1 (en)
EP (1) EP2387717B1 (en)
JP (2) JP2012515353A (en)
KR (1) KR20110120890A (en)
CN (1) CN102439452B (en)
AU (1) AU2010204576A1 (en)
BR (1) BRPI1007048A2 (en)
CA (1) CA2749817A1 (en)
ES (1) ES2526519T3 (en)
IL (1) IL214067A0 (en)
SG (1) SG172984A1 (en)
WO (1) WO2010083463A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229294A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
US20040091850A1 (en) * 2002-11-08 2004-05-13 Travis Boone Single cell analysis of membrane molecules
US7402398B2 (en) 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
WO2009070772A1 (en) 2007-11-27 2009-06-04 Monogram Biosciences, Inc. Enhanced method for detecting and/or quantifying an analyte in a sample
WO2009086197A1 (en) 2007-12-20 2009-07-09 Monogram Biosciences, Inc. Her-2 diagnostic methods
US8349574B2 (en) 2009-01-15 2013-01-08 Laboratory Corporation Of America Holdings Methods of determining patient response by measurement of Her-3
US20120295259A1 (en) * 2011-05-19 2012-11-22 Laboratory Corporation Of America Holdings Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients
US8470542B2 (en) * 2008-12-01 2013-06-25 Laboratory Corporation Of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
US11401344B2 (en) 2008-12-01 2022-08-02 Laboratory Corporation Of America Holdings Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients
ES2925983T3 (en) 2010-07-27 2022-10-20 Genomic Health Inc Method for using gene expression to determine prostate cancer prognosis
TW201302793A (en) 2010-09-03 2013-01-16 Glaxo Group Ltd Novel antigen binding proteins
FR2993668B1 (en) * 2012-07-17 2015-07-03 Cisbio Bioassays THERANOSTIC METHOD BASED ON THE DETECTION OF HER2-HER2 DIMERS
EP2981828A1 (en) 2013-04-05 2016-02-10 Laboratory Corporation of America Holdings Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation
CN107003323B (en) 2014-11-25 2019-06-04 文塔纳医疗系统公司 Use the proximity assay being connected chemically with haptens transfer
US20180209981A1 (en) * 2015-07-23 2018-07-26 National University Of Singapore Wbp2 as a co-prognostic factor with her2 for stratification of patients for treatment
EP3403095B1 (en) 2016-03-15 2019-08-07 Laboratory Corporation of America Holdings Methods of assessing protein interactions between cells
JP7022123B2 (en) 2016-09-30 2022-02-17 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Bispecific antibody against CD3
JP6922444B2 (en) * 2016-11-11 2021-08-18 コニカミノルタ株式会社 Test support method to support prediction of complete pathological response (pCR) using fluorescent nanoparticles
EP3807640A4 (en) * 2018-06-14 2022-04-13 Memorial Sloan Kettering Cancer Center Methods for predicting responsiveness of lung cancer patients to her2-targeting therapies
KR102317202B1 (en) * 2018-10-19 2021-10-25 주식회사 프로티나 Method for Predicting Recurrence of Breast Cancer
KR20230134232A (en) 2022-03-14 2023-09-21 부산대학교 산학협력단 Multiple Biomarker Composition for Predicting Drug Responsiveness to Platinum-based Anti-cancer Agents in Ovarian Cancer and Method for Diagnosing Using The Same Marker

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE240395T1 (en) * 1994-03-29 2003-05-15 Celltech Therapeutics Ltd ANTIBODIES AGAINST E-SELECTIN
SE9601676D0 (en) * 1996-04-30 1996-04-30 Ulf Landegren Improved probing of specific mucleic acids
US6335479B1 (en) * 1998-10-13 2002-01-01 Dai Nippon Printing Co., Ltd. Protective sheet for solar battery module, method of fabricating the same and solar battery module
US6541214B1 (en) * 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
US6682887B1 (en) * 1999-04-30 2004-01-27 Aclara Biosciences, Inc. Detection using degradation of a tagged sequence
US6514700B1 (en) * 1999-04-30 2003-02-04 Aclara Biosciences, Inc. Nucleic acid detection using degradation of a tagged sequence
US6322980B1 (en) * 1999-04-30 2001-11-27 Aclara Biosciences, Inc. Single nucleotide detection using degradation of a fluorescent sequence
US6627400B1 (en) * 1999-04-30 2003-09-30 Aclara Biosciences, Inc. Multiplexed measurement of membrane protein populations
US20040248150A1 (en) * 1999-04-02 2004-12-09 Sharat Singh Methods employing oligonucleotide-binding e-tag probes
US7037654B2 (en) * 1999-04-30 2006-05-02 Aclara Biosciences, Inc. Methods and compositions for enhancing detection in determinations employing cleavable electrophoretic tag reagents
US7001725B2 (en) * 1999-04-30 2006-02-21 Aclara Biosciences, Inc. Kits employing generalized target-binding e-tag probes
US6649351B2 (en) * 1999-04-30 2003-11-18 Aclara Biosciences, Inc. Methods for detecting a plurality of analytes by mass spectrometry
US20030092012A1 (en) * 2001-11-09 2003-05-15 Ahmed Chenna Methods for detecting a plurality of analytes by chromatography
US20030235832A1 (en) * 2000-06-21 2003-12-25 Ahmed Chenna Multiplexed analysis by chromatographic separation of molecular tags
US6673550B2 (en) * 1999-04-30 2004-01-06 Aclara Biosciences, Inc. Electrophoretic tag reagents comprising fluorescent compounds
US6162593A (en) * 1999-10-26 2000-12-19 Wyatt; Marion F. Diisopropylbenzene containing solvent and method of developing flexographic printing plates
DE19963849A1 (en) * 1999-12-30 2001-07-12 Giesecke & Devrient Gmbh Data carrier with printed security element
US7306904B2 (en) * 2000-02-18 2007-12-11 Olink Ab Methods and kits for proximity probing
US6743911B2 (en) * 2000-03-14 2004-06-01 Shell Oil Company Process for the carbonylation of pentenenitrile
GB0007911D0 (en) * 2000-03-30 2000-05-17 Novartis Ag Organic compounds
US7537938B2 (en) * 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
US7160735B2 (en) * 2000-04-28 2007-01-09 Monogram Biosciences, Inc. Tagged microparticle compositions and methods
US7771929B2 (en) * 2000-04-28 2010-08-10 Monogram Biosciences, Inc. Tag library compounds, compositions, kits and methods of use
US20030207300A1 (en) * 2000-04-28 2003-11-06 Matray Tracy J. Multiplex analytical platform using molecular tags
US20040067498A1 (en) * 2000-04-28 2004-04-08 Ahmed Chenna Detection of nucleic acid sequences by cleavage and separation of tag-containing structures
EP1309717A1 (en) * 2000-08-08 2003-05-14 Aclara BioSciences, Inc. Multiplexed enzymatic assays
ES2394293T3 (en) * 2001-02-28 2013-01-30 Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. Vaccine against cancers that are associated with the HER-2 / neu oncogene
US7183388B2 (en) * 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
PL373962A1 (en) * 2001-05-21 2005-09-19 Aclara Biosciences, Inc. Methods and compositions for analyzing proteins
WO2002094998A2 (en) * 2001-05-21 2002-11-28 Aclara Biosciences, Inc. Analyzing phosphorylated proteins
AU2002344221A1 (en) * 2001-05-26 2002-12-09 Aclara Biosciences, Inc. Catalytic amplification of multiplexed assay signals
US7446185B2 (en) * 2001-07-18 2008-11-04 The Regents Of The University Of California Her2/neu target antigen and use of same to stimulate an immune response
WO2003008968A2 (en) * 2001-07-19 2003-01-30 Signet Laboratories, Inc. Human tissue specific drug screening procedure
GB2378245A (en) * 2001-08-03 2003-02-05 Mats Nilsson Nucleic acid amplification method
WO2003033741A1 (en) * 2001-10-16 2003-04-24 Aclara Biosciences, Inc. Universal e-tag primer and probe compositions and methods
US7045311B2 (en) * 2001-10-25 2006-05-16 Monogram Biosciences, Inc. Whole cell assay systems for cell surface proteases
US6659577B2 (en) * 2001-12-06 2003-12-09 Hewlett-Packard Development Company, L.P. Dual flat springs for tool-less slide installation
US7135174B2 (en) * 2002-01-07 2006-11-14 Amgen Fremont, Inc. Antibodies directed to PDGFD and uses thereof
ES2352180T3 (en) * 2002-02-26 2011-02-16 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. MONOCLONAL ANTIBODY OF HUMAN ANTI-TENASCINE.
AU2003222253A1 (en) * 2002-03-05 2003-09-22 Monogram Biosciences, Inc. Multiplex analysis using membrane-bound sensitizers
ES2486265T3 (en) * 2002-03-13 2014-08-18 Genomic Health, Inc. Obtaining gene expression profile in biopsied tumor tissues
CA2480175A1 (en) * 2002-04-02 2003-10-16 Aclara Biosciences, Inc. Multiplexed assays using electrophoretically separated molecular tags
US20040248151A1 (en) * 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
US7332580B2 (en) * 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US7402397B2 (en) * 2002-05-21 2008-07-22 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
US20040229293A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui Surface receptor complexes as biomarkers
US20040229294A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
US20090111127A1 (en) * 2002-05-21 2009-04-30 Monogram Biosciences Inc. Surface Receptor Complexes as Biomarkers
US20040229380A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
US20040229299A1 (en) * 2002-05-21 2004-11-18 Badal M. Youssouf Intracellular complexes as biomarkers
US20040175765A1 (en) * 2002-07-05 2004-09-09 Sharat Singh Cell-screening assay and composition
RU2338751C2 (en) * 2002-07-15 2008-11-20 Дженентек, Инк. MEANS OF IDENTIFICATION OF TUMOURS, ACQUISITIVE TO TREATMENT BY ANTIBODIES AGAINST ErbB2
WO2004011900A2 (en) * 2002-07-25 2004-02-05 Aclara Biosciences, Inc. Detecting receptor oligomerization
WO2004010842A2 (en) * 2002-07-26 2004-02-05 Aclara Biosciences, Inc. Lipophilic electrophoretic probes
US20040091850A1 (en) * 2002-11-08 2004-05-13 Travis Boone Single cell analysis of membrane molecules
AU2004230700A1 (en) * 2003-04-01 2004-10-28 Monogram Biosciences, Inc. Surface receptor complexes as biomarkers
US20100291594A1 (en) * 2003-07-17 2010-11-18 Laboratory Corporation Of America Holdings ErbB Surface Receptor Complexes as Biomarkers
US7402398B2 (en) * 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
WO2005011607A2 (en) * 2003-08-01 2005-02-10 Smithkline Beecham Corporation Treatment of cancers expressing p95 erbb2
WO2005019470A2 (en) * 2003-08-11 2005-03-03 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
EP1664716A4 (en) * 2003-08-15 2008-08-13 Smithkline Beecham Corp Biomarkers in cancer
US20050106571A1 (en) * 2003-10-02 2005-05-19 The Regents Of The University Of California Mammalian T1R3 sweet taste receptors
EP1681983A4 (en) * 2003-10-14 2008-12-10 Monogram Biosciences Inc Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
PL1674111T3 (en) * 2004-07-09 2011-04-29 Chugai Pharmaceutical Co Ltd Anti-glypican 3 antibody
WO2006044748A2 (en) * 2004-10-15 2006-04-27 Monogram Biosciences, Inc. RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
EP1842226B2 (en) * 2004-11-03 2014-07-02 Iris International, Inc. Homogeneous analyte detection
US7939267B2 (en) * 2004-11-04 2011-05-10 Laboratory Corporation Of America Holdings Detection of activation of endothelial cells as surrogate marker for angiogenesis
US7862995B2 (en) * 2004-12-10 2011-01-04 Targeted Molecular Diagnostics Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
US20060212956A1 (en) * 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
JP2006316040A (en) * 2005-05-13 2006-11-24 Genentech Inc Herceptin(r) adjuvant treatment
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
CN1928563B (en) * 2005-09-09 2010-04-28 上海张江生物技术有限公司 Immunodiagnosis reagent kit for breast cancer and test slip
WO2009070772A1 (en) * 2007-11-27 2009-06-04 Monogram Biosciences, Inc. Enhanced method for detecting and/or quantifying an analyte in a sample
CN101230390A (en) * 2007-12-07 2008-07-30 湖北大学 Gene chip for gynecologic malignant tumor early screening and detection method thereof
WO2009086197A1 (en) * 2007-12-20 2009-07-09 Monogram Biosciences, Inc. Her-2 diagnostic methods
US8349574B2 (en) * 2009-01-15 2013-01-08 Laboratory Corporation Of America Holdings Methods of determining patient response by measurement of Her-3
US8470542B2 (en) * 2008-12-01 2013-06-25 Laboratory Corporation Of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95

Also Published As

Publication number Publication date
IL214067A0 (en) 2011-08-31
US20140370523A1 (en) 2014-12-18
US20100233732A1 (en) 2010-09-16
AU2010204576A1 (en) 2011-09-01
JP2012515353A (en) 2012-07-05
EP2387717A1 (en) 2011-11-23
CN102439452B (en) 2015-04-15
WO2010083463A9 (en) 2010-12-23
WO2010083463A1 (en) 2010-07-22
EP2387717B1 (en) 2014-12-10
US20170082626A1 (en) 2017-03-23
KR20110120890A (en) 2011-11-04
JP2014074724A (en) 2014-04-24
CN102439452A (en) 2012-05-02
BRPI1007048A2 (en) 2016-02-10
ES2526519T3 (en) 2015-01-13
EP2387717A4 (en) 2012-09-26
SG172984A1 (en) 2011-08-29
JP5615986B2 (en) 2014-10-29

Similar Documents

Publication Publication Date Title
CA2749817A1 (en) Methods of determining patient response by measurement of her-2 expression
JP2012515353A5 (en)
Villaflor et al. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer
Harbeck et al. Molecular and protein markers for clinical decision making in breast cancer: today and tomorrow
AU2004258085B2 (en) Expression profile algorithm and test for cancer prognosis
Sueta et al. Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer; is it equally useful across tumor subtypes?
ES2812105T3 (en) Algorithm and evaluation of the gene expression profile to determine the prognosis of prostate cancer
Ignatiadis et al. Understanding the molecular basis of histologic grade
Ross Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome
EP2082065A1 (en) Multigene prognostic assay for lung cancer
Chen et al. Clinical and pathological response to neoadjuvant chemotherapy based on primary tumor reduction is correlated to survival in hormone receptor-positive but not hormone receptor-negative locally advanced breast cancer
Martin-Castillo et al. Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer
Iwamoto et al. Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers
Garufi et al. Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?
Wang et al. Perioperative circulating tumor cells (CTCs), MCTCs, and CTC-white blood cells detected by a size-based platform predict prognosis in renal cell carcinoma
Rausch et al. Muscle-invasive bladder cancer is characterized by overexpression of thymidine kinase 1
da Luz et al. The current staging and classification systems of breast cancer and their pitfalls: Is it possible to integrate the complexity of this neoplasm into a unified staging system?
ES2914727T3 (en) Algorithms and methods to evaluate late clinical criteria in prostate cancer
Onoda et al. The value of progesterone receptor expression in predicting the recurrence score for hormone-receptor positive invasive breast cancer patients
Siddappa et al. Gene expression analysis to detect disseminated tumor cells in the bone marrow of triple-negative breast cancer patients predicts metastatic relapse
Dancik et al. A 20 gene model for predicting nodal involvement in bladder cancer patients with muscle invasive tumors
CN114350799A (en) Application of HTR2C in prognosis of low-grade glioma
Yue et al. RT-qPCR is helpful to distinguish the clinicopathological features of HER2 immunohistochemistry 0 and 1+
Guldvik et al. Low blood levels of LRG1 before radical prostatectomy identify patients with high risk of progression to castration-resistant prostate cancer
TWI817224B (en) Method and kit for predicting breast cancer prognosis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140708

FZDE Discontinued

Effective date: 20191023

FZDE Discontinued

Effective date: 20191023